The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site prior to surgical resection of the tumor. Patients will receive the standard of care, including radiation and Temodar therapy and two out of three will additionally receive DCVax-L, with the remaining one third receiving a placebo. All patients will have the option to receive DCVax-L in a crossover arm upon documented disease progression. (note: DCVax-L when used for patients with brain cancer is sometimes also referred to as DCVax-Brain)

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

McGovern Medical School - ACTAT - Research Department

UCSD Moores Cancer Center

Newport Beach, CA

Northwest Biotherapeutics

In summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local control or prolonged overall survival. As discussed above it seems unlikely that patient outcomes will be significantly improved with radiation dose escalation given at the time of the EBRT boost. However, as most failures are local, improving LC could potentially improve the OS of patients. To do this, we propose a shift in the traditional radiation paradigm. This study will assess the feasibility and tolerability of adding GT radiation therapy as an upfront boost at the time of maximum safe resection, along with the backbone of the current standard of care approach, concomitant and adjuvant temozolomide +/- TTF, for patients with newly diagnosed GBM. GT, a novel brain brachytherapy device utilizing Cs-131 embedded in bioresorbable collagen tiles, offers a more sophisticated carrier and a shorter half-life radioisotope, Cs-131. Use of this device allows for radiation initiation at an earlier time point and a more rapid dose delivery and possibly more effective tumor control particularly for rapidly proliferating tumors such as GBM. Two prospective studies have demonstrated the safety and efficacy of re-irradiation with GT in patients with recurrent GBM. The overarching goal of this single-arm, open label phase 4 study is to determine the feasibility and tolerability of treating patients with GammaTile in combination with the Stupp Protocol and how to proceed with testing this treatment in a future, larger, randomized clinical study. The aims of the study are to demonstrate that the use of GammaTile at the time of surgery is well tolerated and does not delay the start of the Stupp protocol. Efficacy outcomes (e.g., LC, OS, PFS) will also be described.

Find clinical trials for Glioblastoma (GBM) in Indianapolis, IN

Related conditions:

Glioblastoma (GBM) trials near Indianapolis, IN, USA:

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

GammaTile and Stupp in Newly Diagnosed GBM (GESTALT)

Find clinical trials for Glioblastoma (GBM) in .css-epvm6{white-space:nowrap;}Indianapolis, IN

Related conditions:

Glioblastoma (GBM) trials near Indianapolis, IN, USA:

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

GammaTile and Stupp in Newly Diagnosed GBM (GESTALT)

Find clinical trials for Glioblastoma (GBM) in Indianapolis, IN